Free tool
FAERS Monitor: Exondys 51
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206488 or its brand name (Exondys 51, Eteplirsen). Reports on generic versions are filed under their own applications.
Reports
2,414
Serious
495
21% of reports
Hospitalization
356
Death reported
68
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue697
- no adverse event550
- intentional dose omission279
- poor venous access187
- device issue182
- pyrexia110
- covid-1987
- malaise74
- pneumonia64
- fall62
- cough56
- illness55
- influenza52
- product dose omission41
- vomiting41
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 48 |
| 2018 | 223 |
| 2019 | 155 |
| 2020 | 193 |
| 2021 | 255 |
| 2022 | 246 |
| 2023 | 387 |
| 2024 | 340 |
| 2025 | 325 |
| 2026 | 240 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,745 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| poor venous accessSignal | 187 | 160.3 | 139.5 | 28,933 |
| intentional dose omissionSignal | 279 | 86.1 | 77.1 | 23,184 |
| no adverse eventSignal | 550 | 26.5 | 24.6 | 13,560 |
| product dose omission issueSignal | 697 | 20.7 | 19.4 | 13,200 |
| device issueSignal | 182 | 17.7 | 15.4 | 2,860 |
| product dose omissionSignal | 41 | 5.5 | 4.0 | 146 |
| illnessSignal | 55 | 4.7 | 3.6 | 155 |
| covid-19Signal | 87 | 4.3 | 3.5 | 221 |
| influenzaSignal | 52 | 4.1 | 3.1 | 118 |
| pyrexiaSignal | 110 | 2.8 | 2.3 | 125 |
| cough | 56 | 1.7 | 1.3 | 17 |
| pneumonia | 64 | 1.7 | 1.4 | 19 |
| fall | 62 | 1.6 | 1.3 | 14 |
| malaise | 74 | 1.5 | 1.2 | 11 |
| vomiting | 41 | 0.8 | 0.6 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.